SUBSCRIBE
SUBSCRIBE

Gossamer Bio

NEWS
Business
Licensing Deals Struck for Liver Disease and IBD Treatments
This morning two companies announced deals that will yield potential benefits to multiple patient populations.
June 25, 2018
 · 
2 min read
 · 
Alex Keown
Business
The Latest Biotech Startups to Watch
A look at the latest startups that have emerged in 2018 so far.
January 8, 2018
 · 
1 min read
Business
Two Former Receptos Execs Launch New San Diego Biotech Startup With $100M
It is not clear what the new company’s focus is just yet.
January 4, 2018
 · 
2 min read
 · 
Mark Terry
Load More
AWARDS
  • NextGen Class of 2019
JOBS
IN THE PRESS
Press Releases
Gossamer Bio Announces Fourth Quarter and Full-Year 2025 Financial Results and Provides Corporate Update
March 18, 2026
 · 
9 min read
Press Releases
Gossamer Bio Announces Topline Results from the Phase 3 PROSERA Study Evaluating Seralutinib in Pulmonary Arterial Hypertension
February 23, 2026
 · 
11 min read
Press Releases
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - January 8, 2026
January 9, 2026
 · 
1 min read
Press Releases
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - December 9, 2025
December 10, 2025
 · 
1 min read
Press Releases
Gossamer Bio to Participate in Upcoming December 2025 Investor Conferences
November 25, 2025
 · 
1 min read
Press Releases
Gossamer Bio to Participate in Upcoming November 2025 Investor Conferences
November 10, 2025
 · 
1 min read
Press Releases
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - November 7, 2025
November 10, 2025
 · 
1 min read
Press Releases
Gossamer Bio Announces Third Quarter 2025 Financial Results and Provides Business Update
November 5, 2025
 · 
10 min read
Press Releases
Respira Therapeutics Enters into Agreement with Gossamer Bio (Gossamer) Granting Gossamer Option to Acquire Respira from Samsara BioCapital
September 26, 2025
 · 
4 min read
Press Releases
Gossamer Bio Enters into Option Agreement to Acquire Respira Therapeutics and Its Lead Candidate, RT234, an Inhaled, On‑Demand Vardenafil for Pulmonary Hypertension
September 26, 2025
 · 
7 min read
Load More